September 27, 2013
JP Morgan settlement criticized
The Securities and Exchange Commission settlement of a case against JPMorgan without charging any top executives, was heavily criticized by Jesse Eisinger, a finance reporter for ProPublica in a New York...
September 23, 2013
FDA bans Ranbaxy imports – again – for pharma manufacturing concerns
For the third time in five years, the U.S. Food and Drug Administration has blocked imports of medicine from a Ranbaxy Laboratories Ltd. plant in India for manufacturing violations. The latest ban involves...
Posted In Whistleblower Law Insights
September 16, 2013
Vanderbilt University hospital accused of failing to supervise doctors and nurses in training during surgeries
A “qui tam” lawsuit against the Vanderbilt University Medical Center that was unsealed last week contained a particularly disturbing allegation: It cited an incident where an unsupervised student nurse...
Posted In Whistleblower Law Insights
September 13, 2013
Bayer AG is the latest pharma company to acknowledge it is being investigated by Chinese authorities for its marketing and sales practices in China
Given the growing number of pharma companies in China under investigation for bribery and corruption, it’s becoming more a question of who isn’t being investigated, rather than who is. Pharma companies...
Posted In Whistleblower Law Insights
September 11, 2013
Glaxo getting squeezed by three countries for pharma marketing practices in China
After getting slapped by the U.S. in 2012 for its marketing practices, GlaxoSmithKline now is getting pummeled by China, the UK, and the U.S. which are investigating Glaxo for its pharma marketing practices...
Posted In Whistleblower Law Insights